Fintel reports that on April 2, 2025, BTIG initiated coverage of NRx Pharmaceuticals (NasdaqCM:NRXP) with a Buy ...

BTIG Research assumed coverage on shares of NRx Pharmaceuticals (NASDAQ:NRXP – Free Report) in a research report released on Wednesday morning, MarketBeat reports. The brokerage issued a buy rating ...

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They ...

BTIG initiated coverage of NRx Pharmaceuticals (NRXP) with a Buy rating and $18 price target NRx Pharmaceuticals is working broadly in ...

NRx Pharmaceuticals (NRXP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions ...

Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and Full Year 2024 Earnings Call. At this time, all lines are in a listen only mode. Following the presentation ...

Both have anticipated PDUFA dates prior to December 31, 2025 The Company has accepted non-binding potential terms from a commercial pharmaceutical company to license and distribute NRX-100 ...

Hope Therapeutics, an interventional psychiatry network wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a definitive agreement ...

WILMINGTON, Del., March 17, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company ...

Fintel reports that on April 2, 2025, BTIG initiated coverage of NRx Pharmaceuticals (MUN:B1Q) with a Buy recommendation. What is the Fund Sentiment? There are 31 funds or institutions reporting ...